RCC, HCC and thyroid cancer have been approved for treatment with VEGFR2 TKIs such as sunitinib (RCC), sorafenib (RCC, HCC), pazopanib (RCC), axitinib (RCC) or vandetanib (MTC). This evidence concerns the gene KDR and thyroid gland carcinoma.